Literature DB >> 19666759

Evaluating health-related quality of life, work ability, and disability in pulmonary arterial hypertension: an unmet need.

Melvyn Rubenfire1, Giuseppina Lippo2, Bruno D Bodini3, Francesco Blasi3, Luigi Allegra3, Eduardo Bossone3.   

Abstract

To our knowledge, there are no specific and validated measures of quality of life (QoL) or degree of disability for pulmonary arterial hypertension (PAH). A review of the literature shows that, with the exception of one recently designed specifically for pulmonary hypertension, QoL questionnaires used in PAH studies are generic measures. These are selected because of shared symptoms that do not necessarily correlate well with functional or physiologic measures and have not been validated for applicability in PAH. In this review, we present the available QoL tools for pulmonary artery hypertension and describe the need for more specific instruments that consider the physical and emotional implications of the diseases associated with PAH and the impact of various treatment options. We also discuss the impact of PAH on work ability and the need for provisions to address medical disability status and Social Security benefit status.

Entities:  

Mesh:

Year:  2009        PMID: 19666759     DOI: 10.1378/chest.08-1260

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  19 in total

1.  Physician attitudes toward palliative care for patients with pulmonary arterial hypertension: results of a cross-sectional survey.

Authors:  Eric R Fenstad; Tait D Shanafelt; Jeff A Sloan; Paul J Novotny; Louise A Durst; Robert P Frantz; Michael D McGoon; Keith M Swetz
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

Review 2.  Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension.

Authors:  Shuyan Gu; Huimei Hu; Hengjin Dong
Journal:  Pharmacoeconomics       Date:  2016-08       Impact factor: 4.981

3.  Exercise capacity affects quality of life in patients with pulmonary hypertension.

Authors:  Michael Halank; Franziska Einsle; Stephanie Lehman; Hinrich Bremer; Ralf Ewert; Heinrike Wilkens; F Joachim Meyer; Ekkehard Grünig; Hans-Jürgen Seyfarth; Martin Kolditz; Gesine Wieder; Gert Höffken; Volker Köllner
Journal:  Lung       Date:  2013-05-17       Impact factor: 2.584

4.  Symptom Interference Severity and Health-Related Quality of Life in Pulmonary Arterial Hypertension.

Authors:  Lea Ann Matura; Annette McDonough; Diane L Carroll
Journal:  J Pain Symptom Manage       Date:  2015-08-20       Impact factor: 3.612

5.  Inpatient Palliative Care Use in Patients With Pulmonary Arterial Hypertension: Temporal Trends, Predictors, and Outcomes.

Authors:  Vidhu Anand; Saraschandra Vallabhajosyula; Wisit Cheungpasitporn; Robert P Frantz; Hector R Cajigas; Jacob J Strand; Hilary M DuBrock
Journal:  Chest       Date:  2020-08-12       Impact factor: 9.410

6.  Improving patient care in pulmonary arterial hypertension: addressing psychosocial issues.

Authors:  Iraklis Tsangaris
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-02-20       Impact factor: 3.738

7.  Exercise Capacity and Quality of Life in Pulmonary Arterial Hypertension.

Authors:  Ling-Wei Chen; Ssu-Yuan Chen; Hsao-Hsun Hsu; Yen-Wen Wu; Yu-Mei Lai; Meng-Yueh Chien
Journal:  Acta Cardiol Sin       Date:  2021-01       Impact factor: 2.672

8.  Association Between Hemodynamic Profile, Physical Capacity and Quality of Life in Pulmonary Hypertension.

Authors:  Diego de Faria Magalhães Torres; Walter Araujo Zin; Agnaldo José Lopes; Patrícia dos Santos Vigário; Marcelo Iorio Garcia; Daniel Waetge; Marcelo Luiz da Silva Bandeira; Luiz Gustavo Pignataro Bessa; Fernando Silva Guimarães
Journal:  Arq Bras Cardiol       Date:  2015-02-27       Impact factor: 2.000

9.  Updating clinical endpoint definitions.

Authors:  Paul M Hassoun; Sylvia Nikkho; Erika B Rosenzweig; Gail Moreschi; John Lawrence; John Teeter; Christian Meier; Ardeshir H Ghofrani; Omar Minai; Paula Rinaldi; Evangelos Michelakis; Ronald J Oudiz
Journal:  Pulm Circ       Date:  2013-01       Impact factor: 3.017

10.  Psychometric performance of the CAMPHOR and SF-36 in pulmonary hypertension.

Authors:  James Twiss; Stephen McKenna; Louise Ganderton; Sue Jenkins; Mitra Ben-L'amri; Kevin Gain; Robin Fowler; Eli Gabbay
Journal:  BMC Pulm Med       Date:  2013-07-12       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.